EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy

Cristina Zanchi, Monica Locatelli, Domenico Cerullo, Verena Aumiller, Daniela Corna, Daniela Rottoli, Steffen Schubert, Marina Noris, Susanna Tomasoni, Giuseppe Remuzzi, Carlamaria Zoja, Ariela Benigni

Molecular Immunology · 2024

DOI: 10.1016/j.molimm.2024.02.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Immunology, 2024. Verfasst von Cristina Zanchi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranoproliferative, Kidney Diseases, Hereditary Complement Deficiency Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Silence Therapeutics plc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Complement alternative pathway (AP) dysregulation drives C3 glomerulopathy (C3G), a rare renal disorder characterized by glomerular C3 deposition and glomerular damage, for which no effective treatments are available. Blockade of complement C3 is emerging as a viable therapeutic option. In an earlier study we showed that SLN500, a small interfering RNA targeting liver C3 synthesis, was able to limit AP dysregulation and glomerular C3d deposits in mice with partial factor H (FH) deficiency (Cfh+/- mice). Here, we assessed the pharmacological effects of SLN501 - an optimized SLN500 version - in mice with complete FH deficiency (Cfh-/- mice) that exhibit a more severe C3G phenotype. SLN501 effectively prevented liver C3 synthesis, thus limiting AP dysregulation, glomerular C3d deposits and the development of ultrastructural alterations. These data provide firm evidence of the use of siRNA-mediated liver C3 gene silencing as a potential therapy for treating C3G patients with either partial or complete FH loss of function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranoproliferativeKidney DiseasesHereditary Complement Deficiency DiseasesHumansAnimalsMiceComplement C3RNA, Small InterferingComplement Factor HComplement Pathway, Alternative

Stichwörter der Autor:innen

C3 glomerulopathyFH-deficient miceGalNAc-siRNAcomplement alternative pathwaycomplement component 3complement factor H

Substanzen

Complement C3RNA, Small InterferingComplement Factor H

Autor:innen und Institutionen

  • Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy.
  • Silence Therapeutics GmbH, Berlin, Germany.
  • Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy. Electronic address: ariela.benigni@marionegri.it.

Förderung

  • Silence Therapeutics plc

Zitieren

APA

Zanchi, C., Locatelli, M., Cerullo, D., Aumiller, V., Corna, D., Rottoli, D., Schubert, S., Noris, M., Tomasoni, S., Remuzzi, G., Zoja, C., & Benigni, A. (2024). Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy. Molecular Immunology. https://doi.org/10.1016/j.molimm.2024.02.010

Vancouver

Zanchi C, Locatelli M, Cerullo D, Aumiller V, Corna D, Rottoli D, et al. Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy. Molecular Immunology. 2024. doi:10.1016/j.molimm.2024.02.010

BibTeX
@article{Zanchi2024,
  author = {Zanchi, Cristina and Locatelli, Monica and Cerullo, Domenico and Aumiller, Verena and Corna, Daniela and Rottoli, Daniela and Schubert, Steffen and Noris, Marina and Tomasoni, Susanna and Remuzzi, Giuseppe and Zoja, Carlamaria and Benigni, Ariela},
  title = {Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy},
  journal = {Molecular Immunology},
  year = {2024},
  doi = {10.1016/j.molimm.2024.02.010}
}
Kostenlos starten →